CMS Wants Narrow Coverage For Biogen's Alzheimer's Drug
The Centers for Medicare & Medicaid Services on Tuesday unveiled its coverage plans for Biogen's Alzheimer's treatment aducanumab, proposing coverage only for individuals taking the controversial drug as part of approved...To view the full article, register now.
Already a subscriber? Click here to view full article